Reviews/Iron Status/Antenatal iron cuts maternal anaemia
Preg · IRON-PREG-01 · v2
The corpus supports the idea that giving iron in pregnancy leaves women less anaemic by the time they deliver, but most of it does not test that question head-on. The one trial that compared iron against a dummy pill [10] shows iron raised blood haemoglobin at delivery in every group of women, and a large observational study in Ghana [11] found that women who received several iron-folic-acid doses had somewhat less anaemia at term. A dosing trial [3] shows that iron works to prevent iron-deficiency anaemia when taken daily but not when taken intermittently. The weakness is that the placebo comparison measured haemoglobin levels rather than counting how many women were anaemic, and much of the rest of the corpus compares one route of iron against another rather than iron against nothing. The direction of effect is consistent and biologically sensible, but the direct proof for the exact outcome is thin, which is why the panel was positive but cautious.
The single placebo-controlled contrast [10] reports higher mean delivery haemoglobin for the iron arm than placebo in the non-anaemia, NIDA and IDA subgroups (8 g/L, 7 g/L and 16 g/L respectively), demonstrating a real physiological effect of iron versus none. A cohort of 5197 women [11] records anaemia at term of 60.57% and finds three or more iron-folic-acid doses reduced risk by only four to six percentage points. A randomised dosing trial [3] concludes intermittent oral iron was not effective at preventing iron-deficiency anaemia, implying adequately dosed daily iron is. Route-comparison studies [2, 5, 9] show oral iron still leaves many women anaemic at term (69.7% non-anaemic in [2]; 61% anaemic in [5]; 67.3% anaemic in [9]), evidence that iron helps but does not resolve anaemia. The contested point: The division is whether the corpus actually isolates iron-versus-no-iron for the anaemia-at-term outcome. The only placebo comparison [10] measures haemoglobin rather than anaemia prevalence and is a secondary analysis, while the only direct anaemia-at-term signal [11] is observational and modest, and the bulk of the corpus [2, 5, 9, 12, 13] compares routes and simply presupposes iron works.
All 13 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Iron Status, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The corpus centre of mass ([2],[5],[8],[9],[12],[13]) compares IV vs oral iron with no placebo arm, so it presupposes iron works and cannot isolate the claim's iron-vs-no-iron contrast.
The only placebo comparison [10] reports a continuous delivery-haemoglobin difference — a surrogate for anaemia prevalence at term — and is a secondary analysis, not a primary anaemia-at-term endpoint.
Where it remains uncertain. The placebo trial [10] reports a haemoglobin surrogate rather than anaemia prevalence, and residual anaemia stayed high in oral-iron arms (61% in [5], 67.3% in [9]), so the effect is partial rather than resolving.
Aleatory
Studies like [7] (N=20, accrual halted) and [3] (N=92) carry wide random error, seen in the very wide interval in [3] (odds ratio 15, 95% CI 1.4-165.6).
Epistemic
No study in the corpus reports anaemia prevalence at term for iron versus placebo; the only placebo arm [10] reports haemoglobin, and [4] which could have added dosing evidence has no results.
Inferential
Inferring lower anaemia prevalence from the delivery-haemoglobin difference in [10] (8, 7 and 16 g/L across subgroups) assumes the surrogate tracks the count outcome.
The load-bearing papers from a corpus of 13, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Shows adequately-dosed daily antenatal iron prevents iron-deficiency anaemia, supporting the dose-dependent protective effect
“Prophylactic oral iron supplements when given intermittently were not effective in preventing iron deficiency anaemia in pregnancy.”
Panel auditInternal validity: low · scope of inference: Prophylactic oral iron dosing frequency in women 14-24 weeks pregnant at one Sri Lankan clinic.Key limitations: small sample · very wide CIs · no no-iron arm
Only iron-vs-placebo contrast in the corpus; iron increases delivery haemoglobin, directly implying reduced maternal anaemia at term
“The difference in the mean delivery hemoglobin for iron supplementation and placebo arms was 8 g/L (95% CI 6, 11) in the non-anemia group, 7 g/L (95% CI 2, 13) in the NIDA group, and 16 g/L (95% CI 10, 22) in the IDA group.”
Panel auditInternal validity: high · scope of inference: HIV-negative Tanzanian pregnant women without severe iron deficiency anaemia, gestational age <27 weeks at baseline; outcome is delivery haemoglobin rather than an anaemia rate.Key limitations: outcome is delivery Hb not anaemia prevalence · excludes severe IDA · secondary analysis
Cohort evidence that antenatal iron dosing reduces anaemia at term, though the effect is modest
“Three or more iron and folic acid doses and eight or more ANC contacts each reduced risk by only four to six percentage points.”
Panel auditInternal validity: medium · scope of inference: Pregnant women at eight facilities in Ghana's Ashanti and Volta regions under declining malaria transmission.Key limitations: observational, confounded · iron combined with folic acid · small effect size · no p-value/CI in abstract
Every arm received iron; the trial measures IV vs oral, not whether iron reduces anaemia relative to no supplementation.
Panel auditInternal validity: high · scope of inference: Second-trimester singleton pregnancies with moderate iron deficiency anaemia in India, comparing routes of iron.Key limitations: no placebo/no-iron arm · route comparison not supplementation vs none
4 of 13 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The corpus genuinely supports the direction of effect but the direct anaemia-at-term-versus-placebo evidence is limited to one secondary analysis and one observational cohort, warranting a Likely rather than Established tier.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No placebo-controlled anaemia-prevalence-at-term trial. The claim's exact outcome is never tested against placebo; [10] uses haemoglobin as a surrogate and is a secondary analysis. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised placebo-controlled trial with maternal anaemia prevalence at term (Hb < 11 g/dL) as the pre-specified primary endpoint.
Open question: Does antenatal iron versus placebo lower the proportion of women anaemic at term, not just raise haemoglobin? Why it is still open: The only placebo contrast [10] reports a delivery-haemoglobin difference rather than anaemia prevalence and is a secondary analysis.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 18 Sep 2026 · protocol v0.19